Company research
Altimmune, Inc.
CIK 1326190Updated Nov 13, 2026
SecurityALT · NASDAQ · equity
Name history
PHARMATHENE, INC · through May 3, 2017HEALTHCARE ACQUISITION CORP · through Oct 15, 2007
ALT price & chart
Loading TradingView…
NASDAQ:ALT on TradingView ↗About the company
Altimmune is a biopharmaceutical company developing pemvidutide for patients with serious liver diseases. Pemvidutide, a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, is in late-stage clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), recently showed robust results in the RECLAIM Phase 2 trial in alcohol use disorder (AUD) and is being studied in alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.
In the news
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 ↗
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration News provided by USA News Group Jan 29, 2026, 13:31 ET Share this article Share to X Share this article Share to X Issued on behalf of Avant Technologies Inc. VANCOUVER, BC , Jan. 29, 2026 /PRNewswire/ -- USA Ne ↗
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm News provided by The Schall Law Firm Oct 07, 2025, 07:24 ET Share this article Share to X Share this article Share to X LOS ANGELES , Oct. 7, 2025 /PRNewswire/ -- The Schall Law Firm , a national ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G - filed by STATE STREET CORP regarding Altimmune, Inc.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 2.03
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 218,447,000Source | 147,864,000Source | 527,212,000Source | 190,350,000Source | 173,346,000Source | 335,630,000Source | 157,263,000Source | 188,358,000Source | 279,929,000Source | 139,306,000Source | 210,640,000Source | 206,928,000Source |
| Property, Plant and Equipment, NetUSD | 337,000Source | 446,000Source | 60,000Source | 364,000Source | 483,000Source | 208,000Source | 384,000Source | 544,000Source | 312,000Source | 413,000Source | 651,000Source | 1,081,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 12,419,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 61,236,000Source | 31,474,000Source | 63,008,000Source | 183,105,000Source | 57,128,000Source | 97,601,000Source | 49,104,000Source | 78,978,000Source | 43,760,000Source | 36,926,000Source | 135,117,000Source | 111,097,000Source |
| Assets, CurrentUSD | 216,615,000Source | 145,759,000Source | 334,815,000Source | 188,422,000Source | 171,186,000Source | 334,676,000Source | 155,262,000Source | 187,515,000Source | 278,192,000Source | 137,254,000Source | 209,626,000Source | 192,813,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,405,000Source | 2,997,000Source | 5,151,000Source | 4,397,000Source | 3,225,000Source | 1,429,000Source | 2,930,000Source | 2,871,000Source | 2,957,000Source | 2,204,000Source | 6,917,000Source | 5,358,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 1,659,000Source | — | — | 1,677,000Source | — | — | 300,000Source | 1,425,000Source | 1,639,000Source | 363,000Source | 596,000Source |
| Other Assets, NoncurrentUSD | 1,495,000Source | 1,659,000Source | 90,000Source | 1,564,000Source | 1,677,000Source | 746,000Source | 1,617,000Source | 299,000Source | 1,425,000Source | 1,639,000Source | 363,000Source | 615,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 32,846,000Source | 14,487,000Source | 53,004,000Source | 28,983,000Source | 20,815,000Source | 51,643,000Source | 15,101,000Source | 15,421,000Source | 55,037,000Source | 15,798,000Source | 16,541,000Source | 21,635,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 10,000Source | 7,000Source | 19,000Source | 9,000Source | 7,000Source | 13,000Source | 8,000Source | 7,000Source | 11,000Source | 7,000Source | 7,000Source | 5,000Source |
| Additional Paid in CapitalUSD | 812,732,000Source | 676,425,000Source | 1,175,098,000Source | 769,508,000Source | 673,081,000Source | 961,244,000Source | 728,122,000Source | 668,816,000Source | 879,292,000Source | 689,864,000Source | 665,427,000Source | 568,399,000Source |
| Retained Earnings (Accumulated Deficit)USD | -622,125,000Source | -538,210,000Source | -694,871,000Source | -603,111,000Source | -515,365,000Source | -672,046,000Source | -580,965,000Source | -490,725,000Source | -649,483,000Source | -561,390,000Source | -466,331,000Source | -377,884,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -5,016,000Source | -4,845,000Source | -6,038,000Source | -5,039,000Source | -5,192,000Source | -5,224,000Source | -5,003,000Source | -5,161,000Source | -4,928,000Source | -4,973,000Source | -5,004,000Source | -5,227,000Source |
| Stockholders' Equity Attributable to ParentUSD | 185,601,000Source | 133,377,000Source | 474,208,000Source | 161,367,000Source | 152,531,000Source | 283,987,000Source | 142,162,000Source | 172,937,000Source | 224,892,000Source | 123,508,000Source | 194,099,000Source | 185,293,000Source |
| Liabilities and EquityUSD | 218,447,000Source | 147,864,000Source | 527,212,000Source | 190,350,000Source | 173,346,000Source | 335,630,000Source | 157,263,000Source | 188,358,000Source | 279,929,000Source | 139,306,000Source | 210,640,000Source | 206,928,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 12,606,000Source | 8,638,000Source | 12,501,000Source | 9,220,000Source | 15,155,000Source | 11,323,000Source | 9,798,000Source | 11,333,000Source | 14,997,000Source | 10,468,000Source | 12,143,000Source | 17,054,000Source |
| Operating Lease, Liability, CurrentUSD | 247,000Source | 313,000Source | 274,000Source | 239,000Source | 345,000Source | 265,000Source | 245,000Source | 508,000Source | 256,000Source | 279,000Source | 496,000Source | 452,000Source |
| Accounts Payable, CurrentUSD | 4,804,000Source | 1,133,000Source | 1,272,000Source | 851,000Source | 2,688,000Source | 1,530,000Source | 1,077,000Source | 3,760,000Source | 2,717,000Source | 211,000Source | 2,070,000Source | 4,804,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,213,000Source | 1,460,000Source | 1,004,000Source | 1,278,000Source | 1,517,000Source | 1,077,000Source | 1,342,000Source | 44,000Source | 1,145,000Source | 1,402,000Source | 175,000Source | 672,000Source |
| Other Liabilities, NoncurrentUSD | 5,795,000Source | 26,000Source | 5,761,000Source | 5,431,000Source | 31,000Source | 5,815,000Source | 16,000Source | 37,000Source | 5,753,000Source | 22,000Source | 40,000Source | 60,000Source |
| Additional Financial Items | ||||||||||||
| Long-term Debt, Excluding Current MaturitiesUSD | 14,445,000Source | — | 34,742,000Source | 14,332,000Source | — | 34,505,000Source | — | — | 34,287,000Source | — | — | 4,581,000Source |
| Short-term InvestmentsUSD | 149,540,000Source | 107,906,000Source | 263,273,000Source | — | 107,780,000Source | 233,939,000Source | 100,722,000Source | 103,046,000Source | 229,696,000Source | 94,965,000Source | 62,698,000Source | 73,783,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -22,563,000Source | -19,575,000Source | -88,093,000Source | -95,059,000Source | -88,447,000Source | -84,713,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,378,000Source | 4,015,000Source | 16,076,000Source | 14,393,000Source | 10,640,000Source | 8,101,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 446,000Source | -37,000Source | 675,000Source | -567,000Source | 938,000Source | -256,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,187,000Source | 866,000Source | 2,506,000Source | -1,859,000Source | -2,734,000Source | 2,770,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | -681,000Source | -681,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -20,942,000Source | -16,840,000Source | -67,535,000Source | -79,848,000Source | -75,810,000Source | -62,586,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -3,690,000Source | -5,101,000Source | -132,473,000Source | -28,386,000Source | 13,732,000Source | -73,399,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 21,000Source | — | 11,000Source | — | 47,000Source | 126,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 695,000Source | 678,000Source | 709,000Source | 850,000Source | 539,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 78,473,000Source | 34,119,000Source | 206,842,000Source | 10,044,000Source | 86,105,000Source | 56,781,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 53,841,000Source | 12,178,000Source | 6,834,000Source | -98,190,000Source | 24,027,000Source | -79,204,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 61,278,000Source | 31,516,000Source | 63,050,000Source | 183,147,000Source | 97,643,000Source | 49,146,000Source | 43,802,000Source | 36,968,000Source | 135,158,000Source | 111,131,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 849,000Source | — | 975,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,554,000Source | 3,078,000Source | 2,788,000Source | 3,566,000Source | 3,378,000Source | 4,015,000Source | 16,076,000Source | 14,393,000Source | 10,640,000Source | 8,101,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 218,000Source | — | 363,000Source | — | — | — |
| DepreciationUSD | — | — | — | — | — | — | 23,000Source | 29,000Source | 112,000Source | 238,000Source | 477,000Source | 500,000Source |
| Depreciation, Amortization and Accretion, NetUSD | — | — | — | — | — | — | — | — | — | — | — | -205,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | -154,000Source | 15,000Source | -160,000Source | 48,000Source | 154,000Source | -34,000Source |
| General and Administrative ExpenseUSD | — | — | 5,904,000Source | 4,969,000Source | 7,574,000Source | 5,691,000Source | 8,052,000Source | 5,993,000Source | 28,098,000Source | 20,966,000Source | 18,137,000Source | 17,134,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 12,419,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | -681,000Source | -681,000Source | — | — | -197,000Source |
| InterestExpenseNonoperatingUSD | — | — | 495,000Source | 6,000Source | 1,097,000Source | 264,000Source | 1,068,000Source | 1,000Source | 1,636,000Source | 9,000Source | — | — |
| Investment Income, InterestUSD | — | — | 2,426,000Source | 1,910,000Source | 4,526,000Source | 1,132,000Source | 2,901,000Source | 1,545,000Source | 7,541,000Source | 8,074,000Source | 7,351,000Source | 2,870,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -19,014,000Source | -22,845,000Source | -22,825,000Source | -22,146,000Source | -22,563,000Source | -19,575,000Source | -88,093,000Source | -95,059,000Source | -88,447,000Source | -84,713,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,845,000Source | 1,922,000Source | 3,404,000Source | 776,000Source | 1,681,000Source | 1,559,000Source | 5,715,000Source | 8,113,000Source | 7,482,000Source | 2,830,000Source |
| Operating ExpensesUSD | — | — | 20,864,000Source | 24,772,000Source | 26,229,000Source | 22,927,000Source | 24,244,000Source | 21,820,000Source | 94,530,000Source | 103,192,000Source | 96,355,000Source | 87,672,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 100,000Source | — | — | — | — | 600,000Source | 500,000Source | 500,000Source | 500,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -86,000Source | 18,000Source | -25,000Source | -92,000Source | -152,000Source | 15,000Source | -190,000Source | 48,000Source | 166,000Source | -32,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 8,742,000Source | 34,748,000Source | 173,733,000Source | 9,994,000Source | 86,601,000Source | 56,166,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | 35,000,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 4,000Source | 41,000Source | 439,000Source | 113,000Source | 434,000Source |
| Proceeds from (Payments for) Other Financing Activities | — | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 5,000Source | 5,000Source | — | 5,000Source | — | 5,000Source | 41,000Source | 20,000Source | 426,000Source | -68,000Source |
| Operating Income (Loss)USD | — | — | -20,859,000Source | -24,767,000Source | -26,229,000Source | -22,922,000Source | -24,244,000Source | -21,815,000Source | -94,489,000Source | -103,172,000Source | -95,929,000Source | -87,740,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -86,000Source | 18,000Source | -25,000Source | -92,000Source | -152,000Source | 15,000Source | -190,000Source | 48,000Source | 166,000Source | -32,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -19,014,000Source | -22,845,000Source | -22,825,000Source | -22,146,000Source | -22,563,000Source | -20,256,000Source | -88,774,000Source | -95,059,000Source | -88,447,000Source | -84,910,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | -681,000Source | -681,000Source | — | — | -197,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -19,014,000Source | -22,845,000Source | -22,825,000Source | -22,146,000Source | -22,563,000Source | -19,575,000Source | -88,093,000Source | -95,059,000Source | -88,447,000Source | -84,713,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.21Source | -0.32Source | -0.12Source | -0.27Source | -0.18Source | -0.26Source | -1Source | -1.34Source | -1.66Source | -1.81Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.21Source | -0.32Source | -0.12Source | -0.27Source | -0.18Source | -0.26Source | -1Source | -1.34Source | -1.66Source | -1.81Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 89,418,028Source | 71,084,787Source | 185,443,736Source | 81,477,548Source | 124,461,818Source | 75,547,746Source | 88,104,132Source | 71,003,399Source | 53,246,937Source | 46,926,349Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 89,418,028Source | 71,084,787Source | 185,443,736Source | 81,477,548Source | 124,461,818Source | 75,547,746Source | 88,104,132Source | 71,003,399Source | 53,246,937Source | 46,926,349Source |
| Interest Expense (non-operating)USD | — | — | 495,000Source | 6,000Source | 1,097,000Source | 264,000Source | 1,068,000Source | 1,000Source | 1,636,000Source | 9,000Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 5,904,000Source | 4,969,000Source | 7,574,000Source | 5,691,000Source | 8,052,000Source | 5,993,000Source | 28,098,000Source | 20,966,000Source | 18,137,000Source | 17,134,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -85,248,000Source | -88,401,000Source | -65,697,000Source | -72,750,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 35,000Source | 8,000Source |
| Investment Income, InterestUSD | — | — | 2,426,000Source | 1,910,000Source | 4,526,000Source | 1,132,000Source | 2,901,000Source | 1,545,000Source | 7,541,000Source | 8,074,000Source | 7,351,000Source | 2,870,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,845,000Source | 1,922,000Source | 3,404,000Source | 776,000Source | 1,681,000Source | 1,559,000Source | 5,715,000Source | 8,113,000Source | 7,482,000Source | 2,830,000Source |
| Operating ExpensesUSD | — | — | 20,864,000Source | 24,772,000Source | 26,229,000Source | 22,927,000Source | 24,244,000Source | 21,820,000Source | 94,530,000Source | 103,192,000Source | 96,355,000Source | 87,672,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 100,000Source | — | — | — | — | 600,000Source | 500,000Source | 500,000Source | 500,000Source |
| Research and Development ExpenseUSD | — | — | 14,960,000Source | 19,803,000Source | 18,655,000Source | 17,236,000Source | 16,192,000Source | 15,827,000Source | 66,432,000Source | 82,226,000Source | 65,799,000Source | 70,538,000Source |
Offerings
Registration 333-295254
Filing attachments
alt-ex99d1.htm · 8-K · 2026-11-12
Exhibit 99.1 Altimmune Announces Third Quarter 2026 Financial Results and Business Update Global PERFORMA Phase 3 trial in MASH progressing as planned Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation at AASLD The Liver Meeting® 2026 End-of-Phase 2 meeting with FDA for AUD program scheduled for December 2026 $480 million in cash, cash equivalents and investments as of September 30, 2026 Webcast to be held today at 8:30 a.m. ET MORRISTOWN, NJ - November…
Read attachment ↗tm2628339d1_ex99-1.htm · 8-K · 2026-10-27
Exhibit 99.1 Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M. Gill, Mitchel Sayare, Ph. D., and Klaus O. Schafer, M.D., MPH, will retire from the Board at the Company’s 2027 Annual Meeting …
Read attachment ↗alt-20260812xex99d1.htm · 8-K · 2026-08-12
EX-99.1 2 alt-20260812xex99d1.htm EX-99.1 Exhibit 99.1 Altimmune Announces Second Quarter 2026 Financial Results and Business Update Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, MD - August 12, 2026 - Altimmune, Inc. (Nasdaq: ALT)…
Read attachment ↗alt-20260728xex99d1.htm · 8-K · 2026-07-28
EX-99.1 2 alt-20260728xex99d1.htm EX-99.1 Exhibit 99.1 Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, including two-level reduction in WHO risk drinking levels and zero heavy drinking days, both of which are recognized by the FDA as …
Read attachment ↗ex99_1.htm · SCHEDULE 13G/A · 2026-05-15
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common stock, par value $0.0001 per share, of Altimmune, Inc. and further agree to the filing of this agreement as an exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to…
Read attachment ↗alt-20260513xex99d1.htm · 8-K · 2026-05-13
EX-99.1 2 alt-20260513xex99d1.htm EX-99.1 Exhibit 99.1 Altimmune Announces First Quarter 2026 Financial Results and Business Update Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of April 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, MD - May 13, 2026 - Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver…
Read attachment ↗